Pharmacists Play Key Role in CIDP ⁤Medication Management

Updated June⁣ 12, 2025

Pharmacists are vital in ⁢managing chronic inflammatory⁣ demyelinating polyneuropathy (CIDP), focusing on medication, patient education, and therapy optimization,⁣ according to Amy duong, a clinical pharmacist at Yale New Haven Health. She emphasized the importance of‍ a multidisciplinary approach in CIDP treatment.

Duong⁢ highlighted the pharmacist’s role in ensuring safe and timely care, working closely with neurologists,‍ nurses, and pharmacy technicians. Pharmacy technicians ⁢assist with logistical⁣ coordination,such as following up on authorization status.⁤ As a clinical pharmacist, Duong provides⁣ comprehensive medication education on therapies like intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIg), efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo), rituximab (Rituxan), and oral steroid tapers.

Pharmacists also support logistical aspects of care, including navigating prior authorizations, coordinating peer-to-peers, ⁢writing⁤ appeal letters, ⁢and scheduling outpatient and home infusions.Clinical follow-up assessments involve evaluating tolerability, reviewing lab work, and‍ monitoring clinical response. The goal is to ensure therapy is clinically effective, accessible, and sustainable within a coordinated care model for chronic inflammatory ⁤demyelinating polyneuropathy.

According to Duong, pharmacists optimize immunoglobulin therapy by individualizing it based on patient history, comorbidities, and tolerability. With expertise in various Ig products, pharmacists guide treatment decisions. For example, they can identify products unsuitable for patients with ⁣uncontrolled type 2 diabetes. close monitoring during infusion ⁤therapies is essential to check for infusion-related reactions and delayed side effects. Mitigation strategies include nonpharmacological approaches, adjusting premedications, ⁤and modifying infusion rates. ⁢Switching to a different Ig product or⁢ mode of governance, such as from IVIg to ⁣SCIg, can also improve tolerability for immunoglobulin therapy.

as an ambulatory care neurology clinical pharmacist, I play a key role in the multidisciplinary ⁤care of our patients with CIDP, mainly focusing on the medication⁤ management aspect,” Duong said.

Pharmacists bring valuable expertise in optimizing Ig therapy by‍ individualizing it based off of the patient’s histories, comorbidities, and tolerability,” said Duong.

What’s next

The role of pharmacists in CIDP management continues to evolve, ⁢with ongoing research and advancements in therapy options promising further improvements in patient⁣ care and outcomes.